Lorin H. Adams

1 Midland Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.

Journal: Emerging infectious diseases
Published: May 29, 2025

Bovine H5N1 binds poorly to human-type sialic acid receptors.

Bovine H5N1 binds poorly to human-type sialic acid receptors.

Journal: Nature
Published: January 15, 2025

Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation.

Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation.

Journal: Influenza and other respiratory viruses
Published: December 06, 2024

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.

Journal: The Lancet. Infectious diseases
Published: April 11, 2024

SARS-CoV-2 mucosal neutralising immunity after vaccination.

SARS-CoV-2 mucosal neutralising immunity after vaccination.

Journal: The Lancet. Infectious diseases
Published: August 25, 2023

Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants.

Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants.

Journal: medRxiv : the preprint server for health sciences
Published: June 09, 2023

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.

Journal: The Lancet. Infectious diseases
Published: April 06, 2023

Differential effects of SARS-CoV-2 variants on central nervous system cells and blood-brain barrier functions.

Differential effects of SARS-CoV-2 variants on central nervous system cells and blood-brain barrier functions.

Journal: Journal of neuroinflammation
Published: March 30, 2023

Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.

Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.

Journal: PLoS biology
Published: March 25, 2023

COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.

COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.

Journal: PloS one
Published: March 10, 2023

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

Journal: Lancet (London, England)
Published: September 26, 2022

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

Journal: Cancer cell
Published: March 30, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026